![]() Several approaches are currently being developed to fight cancer by activating the immune system, such as TLR7, TLR8 and/or TLR9 agonists, as well as activators of the STING pathway and oncolytic viruses. Second, the manner in which CpG-A stimulates TLR9 induces significantly higher levels of type I interferons (IFN-α, etc.) in pDCs compared to other innate immune activators, resulting in a stronger T cell antitumor response. This provides the pDC with an initial stimulatory signal and brings CpG-A to TLR9 (CpG DNA receptor) within the pDC. First, VLPs activate the body to mount an immune response, so that the antibodies produced deliver VLPs to plasmacytoid dendritic cells (pDCs) and to other immune cells via FcR-specific receptors. Vidutolimod acts through two complementary mechanisms to drive robust systemic T cell antitumor responses. dollars.Īffected by the news, Checkmate shares soared 329%.Ĭheckmate's lead investigational candidate, Vidutolimod, is a CpG-A oligodeoxynucleotide toll-like receptor 9 (TLR9) agonist delivered via virus-like particles (VLPs). On April 19, REGENERON and Checkmate jointly announced that the two companies have signed a definitive agreement under which Regeneron will acquire Checkmate common stock at an all-cash price of $10.50 per share, with a proposed total equity value of Checkmate of approximately $2.50.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |